In 2006, Andrew Fire, a professor at Stanford University, and Craig Melo, a professor at the University of Massachusetts, won the Nobel Prize in Physiology or Medicine for their extraordinary RNA interference paper published in the February issue of Nature 1998. After the publication of Farr and Melo's research, researchers all over the world are interested in the field of RNA interference. In the internationally popular research on RNAi interference technology, Professor Song successfully applied RNAi gene interference technology to mouse fulminant hepatitis model for the first time, which confirmed that RNAi is not only a methodology of gene function analysis, but also has great application potential in treating diseases, laying a foundation for the application of this technology to human diseases. Philip Sharp, a professor at MIT and a Nobel Prize winner, called it "the first time to show the therapeutic effect of RNA interference in the whole animal disease model". His research results are being published, and Professor Song is the first author.
Summarizing the previous scientific research results and looking forward to the future work direction, Professor Song said that two important scientific research projects have been completed: First, it has been successfully applied to the whole animal disease model for the first time, which proves the great therapeutic potential of RNAi. Related drugs have been put into the American market, which has a wide application prospect and economic value, and patent applications for related products are also in progress. Secondly, RNA interference drugs and fragment antibody fusion proteins are successfully combined to form a "biological missile", which can accurately kill cancer cells, avoid damage to normal cells, reduce side effects and improve curative effect. Looking forward to the future work direction, he expressed the hope to make progress in the research of cancer stem cells.